{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:50:18Z","timestamp":1792363818754,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Early noninvasive reliable biomarkers are among the major unmet needs in Parkinson\u2019s disease (PD) to monitor therapy response and disease progression. Objective measures of motor performances could allow phenotyping of subtle, undetectable, early stage motor impairments of PD patients. This work aims at identifying prognostic biomarkers in newly diagnosed PD patients and quantifying therapy-response. Forty de novo PD patients underwent clinical and technology-based kinematic assessments performing motor tasks (MDS-UPDRS part III) to assess tremor, bradykinesia, gait, and postural stability (T0). A visit after 6 months (T1) and a clinical and kinematic assessment after 12 months (T2) where scheduled. A clinical follow-up was provided between 30 and 36 months after the diagnosis (T3). We performed an ANOVA for repeated measures to compare patients\u2019 kinematic features at baseline and at T2 to assess therapy response. Pearson correlation test was run between baseline kinematic features and UPDRS III score variation between T0 and T3, to select candidate kinematic prognostic biomarkers. A multiple linear regression model was created to predict the long-term motor outcome using T0 kinematic measures. All motor tasks significantly improved after the dopamine replacement therapy. A significant correlation was found between UPDRS scores variation and some baseline bradykinesia (toe tapping amplitude decrement,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009) and gait features (velocity of arms and legs, sit-to-stand time,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.007;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01, respectively). A linear regression model including four baseline kinematic features could significantly predict the motor outcome (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.000214). Technology-based objective measures represent possible early and reproducible therapy-response and prognostic biomarkers.\n                  <\/jats:p>","DOI":"10.1038\/s41531-021-00227-1","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T06:04:13Z","timestamp":1631858653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Technology-based therapy-response and prognostic biomarkers in a prospective study of a de novo Parkinson\u2019s disease cohort"],"prefix":"10.1038","volume":"7","author":[{"given":"Giulia","family":"Di Lazzaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9034-9921","authenticated-orcid":false,"given":"Giovanni","family":"Saggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Schirinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-4524","authenticated-orcid":false,"given":"Mohammad","family":"Alwardat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pietrosanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Patera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Scalise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8432-594X","authenticated-orcid":false,"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"key":"227_CR1","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1212\/WNL.0b013e318293e2ce","volume":"80","author":"E Ray Dorsey","year":"2013","unstructured":"Ray Dorsey, E., George, B. P., Leff, B. & Willis, A. W. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology. 80, 1989\u20131996 (2013).","journal-title":"Neurology."},{"key":"227_CR2","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","volume":"15","author":"A Ascherio","year":"2016","unstructured":"Ascherio, A. & Schwarzschild, M. A. The epidemiology of Parkinson\u2019 s disease: risk factors and prevention. Lancet Neurol. 15, 1257\u20131272 (2016).","journal-title":"Lancet Neurol."},{"key":"227_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti, L. et al. CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol. 18, 573\u2013586 (2019).","journal-title":"Lancet Neurol."},{"key":"227_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s12264-017-0183-5","volume":"33","author":"S Lotankar","year":"2017","unstructured":"Lotankar, S., Prabhavalkar, K. S. & Bhatt, L. K. Biomarkers for Parkinson\u2019s disease: recent advancement.Neurosci. Bull. 33, 585\u2013597 (2017).","journal-title":"Neurosci. Bull."},{"key":"227_CR5","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/brain\/awx118","volume":"140","author":"S-M Fereshtehnejad","year":"2017","unstructured":"Fereshtehnejad, S.-M., Zeighami, Y., Dagher, A. & Postuma, R. B. Clinical criteria for subtyping Parkinson\u2019s disease: biomarkers and longitudinal progression. Brain 140, 1959\u20137 (2017).","journal-title":"Brain"},{"key":"227_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/mds.27361","volume":"33","author":"T Simuni","year":"2018","unstructured":"Simuni, T. et al. Longitudinal change of clinical and biological measures in early Parkinson\u2019s disease: Parkinson\u2019s progression markers initiative cohort. Mov. Disord. 33, 771\u2013782 (2018).","journal-title":"Mov. Disord."},{"key":"227_CR7","doi-asserted-by":"crossref","unstructured":"Rocha, A. P. et al. Parkinson\u2019s disease assessment based on gait analysis using an innovative RGB-D camera system. In 2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. 3126\u20133129 (EMBC, 2014).","DOI":"10.1109\/EMBC.2014.6944285"},{"key":"227_CR8","first-page":"1","volume":"14","author":"O \u0164upa","year":"2015","unstructured":"\u0164upa, O. et al. Motion tracking and gait feature estimation for recognising Parkinson\u2019s disease using MS Kinect. Biomed. Eng. 14, 1\u201320 (2015).","journal-title":"Biomed. Eng."},{"key":"227_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00415-008-0712-2","volume":"255","author":"S Breit","year":"2008","unstructured":"Breit, S., Spieker, S., Schulz, J. B. & Gasser, T. Long-term EMG recordings differentiate between parkinsonian and essential tremor. J. Neurol. 255, 103\u2013111 (2008).","journal-title":"J. Neurol."},{"key":"227_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0160329","volume":"11","author":"S Argaud","year":"2016","unstructured":"Argaud, S. et al. Does facial amimia impact the recognition of facial emotions? An EMG study in Parkinson\u2019s disease. PLoS ONE 11, 1\u201320 (2016).","journal-title":"PLoS ONE"},{"key":"227_CR11","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1088\/0967-3334\/28\/12\/005","volume":"28","author":"S Rissanen","year":"2007","unstructured":"Rissanen, S. et al. Analysis of surface EMG signal morphology in Parkinson\u2019s disease. Physiol. Meas. 28, 1507\u20131521 (2007).","journal-title":"Physiol. Meas."},{"key":"227_CR12","first-page":"831","volume":"58","author":"S Patel","year":"2010","unstructured":"Patel, S. et al. A web-based system for home monitoring of patients with Parkinson\u2019s disease using wearable sensors. IEEE Trans. Biomed. Eng. 58, 831\u2013836 (2010).","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"227_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jbiomech.2018.12.005","volume":"83","author":"M Ricci","year":"2019","unstructured":"Ricci, M. et al. Wearable-based electronics to objectively support diagnosis of motor impairments in school-aged children. J. Biomech. 83, 243\u2013252 (2019).","journal-title":"J. Biomech."},{"key":"227_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.14639\/0392-100X-1334","volume":"37","author":"M Alessandrini","year":"2017","unstructured":"Alessandrini, M. et al. Body-worn triaxial accelerometer coherence and reliability related to static posturography in unilateral vestibular failure. Acta Otorhinolaryngol. Ital. 37, 231\u2013236 (2017).","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"227_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11517-010-0697-8","volume":"49","author":"JW Kim","year":"2011","unstructured":"Kim, J. W. et al. Quantification of bradykinesia during clinical finger taps using a gyrosensor in patients with Parkinson\u2019s disease. Med Biol. Eng. Comput 49, 365\u2013371 (2011).","journal-title":"Med Biol. Eng. Comput"},{"key":"227_CR16","first-page":"803","volume":"19","author":"M Giuberti","year":"2015","unstructured":"Giuberti, M. et al. Automatic UPDRS evaluation in the sit-to-stand task of parkinsonians: Kinematic analysis and comparative outlook on the leg agility task. IEEE J. Biomed. Heal Inform. 19, 803\u2013814 (2015).","journal-title":"IEEE J. Biomed. Heal Inform."},{"key":"227_CR17","doi-asserted-by":"crossref","unstructured":"Saggio, G. Are sensors and data processing paving the way to completely non-invasive and not-painful medical tests for widespread screening and diagnosis purposes? in BIODEVICES 2020\u201413th International Conference on Biomedical Electronics and Devices, Proceedings; Part of 13th International Joint Conference on Biomedical Engineering Systems and Technologies, BIOSTEC 2020. 207\u2013214, (SciTePress, 2020).","DOI":"10.5220\/0009098002070214"},{"key":"227_CR18","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/mds.26642","volume":"31","author":"AJ Espay","year":"2017","unstructured":"Espay, A. J. et al. Technology in Parkinson disease: challenges and opportunities. Mov. Disord. 31, 1272\u20131282 (2017).","journal-title":"Mov. Disord."},{"key":"227_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2017.00555","volume":"11","author":"E Rovini","year":"2017","unstructured":"Rovini, E., Maremmani, C. & Cavallo, F. How wearable sensors can support parkinson\u2019s disease diagnosis and treatment: a systematic review. Front. Neurosci. 11, 1\u201341 (2017).","journal-title":"Front. Neurosci."},{"key":"227_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3233\/JPD-191758","volume":"10","author":"G Di Lazzaro","year":"2019","unstructured":"Di Lazzaro, G. et al. Technology-based objective measures detect subclinical axial signs in untreated, de novo Parkinson\u2019s disease. J. Parkinsons Dis. 10, 113\u2013122 (2019).","journal-title":"J. Parkinsons Dis."},{"key":"227_CR21","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.3390\/s19245465","volume":"19","author":"M Ricci","year":"2019","unstructured":"Ricci, M. et al. Wearable electronics assess the effectiveness of transcranial direct current stimulation on balance and gait in Parkinson\u2019s disease patients. Sensors 19, 5465 (2019).","journal-title":"Sensors"},{"key":"227_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1109\/JBHI.2019.2903627","volume":"24","author":"M Ricci","year":"2019","unstructured":"Ricci, M. et al. Assessment of motor impairments in early untreated Parkinson\u2019s disease patients: the wearable electronics impact. IEEE J. Biomed. Heal. Inform. 24, 120\u2013130 (2019).","journal-title":"IEEE J. Biomed. Heal. Inform"},{"key":"227_CR23","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/mds.27671","volume":"34","author":"AJ Espay","year":"2019","unstructured":"Espay, A. J. et al. A roadmap for implementation of patient-centered digital outcome measures in Parkinson\u2019s disease obtained using mobile health technologies. Mov. Disord. 34, 657\u2013663 (2019).","journal-title":"Mov. Disord."},{"key":"227_CR24","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.parkreldis.2017.07.022","volume":"46","author":"CA Artusi","year":"2018","unstructured":"Artusi, C. A. et al. Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. Park Relat. Disord. 46, S53\u2013S56 (2018).","journal-title":"Park Relat. Disord."},{"key":"227_CR25","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/archneur.64.5.676","volume":"64","author":"J Jankovic","year":"2007","unstructured":"Jankovic, J., Watts, R. L., Martin, W. & Boroojerdi, B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 64, 676\u2013682 (2007).","journal-title":"Arch Neurol."},{"key":"227_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","volume":"74","author":"AHV Schapira","year":"2017","unstructured":"Schapira, A. H. V. et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations a randomized clinical trial. JAMA Neurol. 74, 216\u2013224 (2017).","journal-title":"JAMA Neurol."},{"key":"227_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira, J. J. et al. Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 15, 154\u2013165 (2016).","journal-title":"Lancet Neurol."},{"key":"227_CR28","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/jamaneurol.2017.3098","volume":"74","author":"AE Bond","year":"2017","unstructured":"Bond, A. E. et al. Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease a randomized Clinical trial. JAMA Neurol. 74, 1412\u20131418 (2017).","journal-title":"JAMA Neurol."},{"key":"227_CR29","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jns.2016.08.028","volume":"369","author":"M Bologna","year":"2016","unstructured":"Bologna, M. et al. Bradykinesia in early and advanced Parkinson\u2019s disease. J. Neurol. Sci. 369, 286\u2013291 (2016).","journal-title":"J. Neurol. Sci."},{"key":"227_CR30","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/mds.23893","volume":"26","author":"AJ Espay","year":"2011","unstructured":"Espay, A. J. et al. Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson\u2019s disease. Mov. Disord. 26, 2504\u20132508 (2011).","journal-title":"Mov. Disord."},{"key":"227_CR31","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/brain\/aws038","volume":"135","author":"H Ling","year":"2012","unstructured":"Ling, H., Massey, L. A., Lees, A. J., Brown, P. & Day, B. L. Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson\u2019s disease. Brain 135, 1141\u20131153 (2012).","journal-title":"Brain"},{"key":"227_CR32","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/mds.27376","volume":"33","author":"F Lipsmeier","year":"2018","unstructured":"Lipsmeier, F. et al. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson\u2019s disease clinical trial. Mov. Disord. 33, 1287\u20131297 (2018).","journal-title":"Mov. Disord."},{"key":"227_CR33","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"227_CR34","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1212\/WNL.0000000000000717","volume":"83","author":"J Verghese","year":"2014","unstructured":"Verghese, J. et al. Motoric cognitive risk syndrome multicountry prevalence and dementia risk. Neurology 83, 718\u2013726 (2014).","journal-title":"Neurology"},{"key":"227_CR35","doi-asserted-by":"crossref","unstructured":"Cohen, J. A., Verghese, J. & Zwerling, J. L. Cognition and gait in older people. 93, 73\u201377 (Elsevier Ltd, 2016).","DOI":"10.1016\/j.maturitas.2016.05.005"},{"key":"227_CR36","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/mds.28055","volume":"35","author":"JE Yoo","year":"2020","unstructured":"Yoo, J. E. et al. Timed up and go test and the risk of Parkinson\u2019s disease: a nation-wide retrospective cohort study. Mov. Disord. 35, 1263\u20131267 (2020).","journal-title":"Mov. Disord."},{"key":"227_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-020-00149-4","volume":"7","author":"RD Markello","year":"2021","unstructured":"Markello, R. D. et al. Multimodal phenotypic axes of Parkinson\u2019s disease. npj Park. Dis. 7, 1\u201312 (2021).","journal-title":"npj Park. Dis."},{"key":"227_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.medengphy.2018.01.008","volume":"54","author":"G Costantini","year":"2018","unstructured":"Costantini, G. et al. Towards the enhancement of body standing balance recovery by means of a wireless audio-biofeedback system. Med. Eng. Phys. 54, 74\u201381 (2018).","journal-title":"Med. Eng. Phys."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00227-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00227-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00227-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T16:56:39Z","timestamp":1670000199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-021-00227-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["227"],"URL":"https:\/\/doi.org\/10.1038\/s41531-021-00227-1","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"assertion":[{"value":"8 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.S. and F.G. own 6% of Captiks srl. Other author declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}